Aislinn Antrim, Managing Editor

Responses elicited by the pneumococcal vaccine for all 20 serotypes were similar whether administered with the COVID-19 vaccine or with placebo.

The FDA granted priority review to the combination of relatlimab and nivolumab in September 2021 based on the results of this study.

Study strongly supports the CDC’s guidance that booster shots are appropriate for anyone ages 16 and older, and that mRNA vaccines are preferred.

Incorporating mental distress screenings during cancer care have been historically difficult, despite the fact that these patients tend to be vulnerable to mental health challenges.

The FGF1 hormone regulates blood glucose by inhibiting fat breakdown, although it works differently than insulin.

There were no instances of participants withdrawing from the study due to an adverse event caused by psilocybin in the treatment of mental health conditions.

The metabolic protein SIRT3 reduces the pools of amino acids that cells use to make proteins and otherwise fuel their growth.

The approval marks the first small interfering RNA therapy for low-density lipoprotein cholesterol reduction.

The existing EUA was also amended to reduce the time for booster dose administration from a minimum of 6 months to at least 5 months following completion of the primary COVID-19 vaccine series.

The Breakthrough Therapy Designation was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study.

More transparent drug pricing could improve patient care.

Modern technology is crucial to the provision of home infusions.

The first and only orally disintegrating tablet form of glycopyrrolate, the product will be launched in early 2022.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

The updated oath has entered into the modern era with more inclusive and contemporary language.

Multiple myeloma has remarkable genetic heterogeneity, which can make it challenging to identify proper prognostication and clinical management for patients.

The treatment was first approved in 2013 for adults as a 1500 mg course of treatment, administered as 2 doses of 750 mg each separated by at least 7 days.

The new analysis includes approximately 1100 women without type 1 or type 2 diabetes (T2D) who subsequently gave birth at least once during the 25-year study period, which ended in 2011.

The safety profile observed in patients with active psoriatic arthritis administered upadacitinib was consistent with the safety profile observed in patients with rheumatoid arthritis.

At week 16, 56.4% of patients receiving tofacitinib achieved an Assessment in SpondyloArthritis International Society 20 response.

Serotypes 22F, 33F, and 3 represent more than a quarter of invasive pneumococcal disease in children under the age of 5

Following the success of ibrutinib, second-generation BTK inhibitors have shown even better outcomes with fewer toxicities.

Pembrolizumab is the first anti-PD-1/anti-PD-L1 therapy to demonstrate a recurrence-free survival benefit in the adjuvant setting for melanoma.

Studies are currently underway to determine the impact of the Omicron COVID-19 variant on the long-acting antibody combination.

Olaparib is a first-in-class PARP inhibitor and is the first targeted treatment to block DNA damage response in cells or tumors with a deficiency in homologous recombination repair.

Based on experience with other variants, Pfizer and BioNTech have high confidence that if needed, they can deliver an Omicron-based COVID-19 vaccine in March 2022.

Amid the current shortage in the pharmacy technician workforce, career ladder programs could improve pharmacy technician recruitment and retention rates.

Using a non-aqueous vehicle and sweeteners to improve palatability, pharmacists and technicians can ensure that young patients remain medication adherent.

Medicine often conflates the social construct of race with biology and fails to address the health-related consequences of systemic racism, according to the presenters.

Pharmacy leaders and organizations should continue to advocate for the expansion of responsibilities granted by the 2020 PREP Act, according to the report.